semaglutide peptide therapy History of glucagon-like peptide-1 receptor agonists Glucagon-like peptide-1 (GLP-1) receptor agonist

The most common side effects were nausea, diarrhea, and fatigue

GLP-1 receptor agonists reduce energy intake by up to roughly 40%, according to a 2025 review of the evidence, and they do it through three overlapping pathways: appetite suppression, delayed gastric emptying, and altered nutrient absorption

Tesamorelin is not indicated for weight loss management (weight neutral effect)

Krug I, Dang AB, Portingale J, Li Y, Won YQ

In a rat model of SNL, intrathecal administration of exendin-4 significantly alleviated pain-induced hippocampal neuroinflammation and enhanced cognitive recovery [68]

Pathophysiology of anaemia: focus on the heart and blood vessels